What is claimed is:

1. ~~A method for administering~~Use of paliperidone palmitate in the manufacture of a medicament for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder int~~o~~ a patient in need thereof who has been administered a first dose of a paliperidone palmitate extended-release injectable suspension, ~~comprising~~ wherein the use comprises ~~administering~~ a second dose of the paliperidone palmitate extended-release injectable suspension to be administered to a deltoid or gluteal muscle of the patient up to two weeks before or three weeks after a time that is six months after administration of the first dose, wherein there is no intervening dose of paliperidone palmitate between the first dose and the second dose.

2. The ~~method~~ use of claim 1, wherein the second dose is to be administered to the gluteal muscle.

3. The ~~method~~ use of claim 1 or claim 2, wherein the patient has a steady state paliperidone plasma concentration at the time of the first dose.

~~4. The method of any one of the preceding claims, wherein the patient is in need of treatment for psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder.~~

~~5~~4. The ~~method~~ use of ~~claim 4~~any one of the preceding claims, wherein the patient is in need of treatment for schizophrenia.

~~6~~5. The ~~method~~ use of any one of the preceding claims, wherein the first dose comprises about 1092 mg of paliperidone palmitate or about 1560 mg of paliperidone palmitate.

~~7~~6. The ~~method~~ use of any one of the preceding claims, wherein the second dose comprises about 1092 mg of paliperidone palmitate or about 1560 mg of paliperidone palmitate.

~~87~~. The ~~method~~ use of any one of the preceding claims, wherein the first dose and the second dose each comprise about 1092 mg paliperidone palmitate.

~~98~~. The ~~method~~ use of any one of claims 1-~~76~~, wherein the first dose and the second dose each comprise about 1560 mg paliperidone palmitate.

~~109~~. The ~~method~~ use of any one of the preceding claims, wherein the plasma concentration of paliperidone in the patient is about 5 to about 50 ng/mL at the time of the second dose.

~~1110~~. The ~~method~~ use of claim ~~109~~, wherein when the first dose comprises 1092 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient is about 5 to about 30 ng/mL at the time of the second dose.

~~1211~~. The ~~method~~ use of claim ~~109~~, wherein when the first dose comprises 1560 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient is about 9 to about 40 ng/mL at the time of the second dose.

~~1312~~. The ~~method~~ use of any one of the preceding claims, wherein the plasma concentration of paliperidone achieves a peak of about 10 to about 150 ng/mL after administration of the second dose.

~~1413~~. The ~~method~~ use of claim ~~1312~~, wherein when the first dose is 1092 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient achieves a peak of about 10 to about 125 ng/mL after administration of the second dose.

~~1514~~. The ~~method~~ use of claim ~~1312~~, wherein when the first dose is 1560 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient achieves a peak of about 35 to about 145 ng/mL after administration of the second dose.

~~1615~~. The ~~method~~ use of any one of the preceding claims, wherein the paliperidone palmitate extended-release injectable suspension comprises:

about 280 mg/mL to about 350 mg/mL of the paliperidone palmitate;
about 8 mg/mL to about 12 mg/mL of a wetting agent;
one or more buffering agents;
about 65 mg/mL to about 85 mg/mL of a suspending agent; and
water q.s. ad 100%.

~~17~~16. The ~~method~~ use of claim ~~16~~15, wherein the suspension is from about pH 6.0 to about pH 8.0.

~~18~~17. The ~~method~~ use of claim ~~16~~ 15 or claim ~~17~~16, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide.

~~19~~18. The ~~method~~ use of claim ~~16~~15, wherein the paliperidone palmitate extended-release injectable suspension comprises:
about 312 mg/mL of paliperidone palmitate;
about 10 mg/mL of polysorbate 20; and
about 75 mg/mL of polyethylene glycol 4000.

19. Paliperidone palmitate for use in therapy.